Full metadata record
DC FieldValueLanguage
dc.contributor.authorKRATOCHWIL CLEMENSen_GB
dc.contributor.authorDOS SANTOS JOSE CARLOSen_GB
dc.contributor.authorLEHNERT WENCKEen_GB
dc.contributor.authorBRUCHERTSEIFER FRANKen_GB
dc.contributor.authorMORGENSTERN ALFREDen_GB
dc.contributor.authorHABERKORN UWEen_GB
dc.contributor.authorKOPKA KLAUSen_GB
dc.contributor.authorMIER WALTERen_GB
dc.date.accessioned2019-04-12T00:02:37Z-
dc.date.available2019-04-11en_GB
dc.date.available2019-04-12T00:02:37Z-
dc.date.created2019-04-09en_GB
dc.date.issued2019en_GB
dc.date.submitted2018-11-05en_GB
dc.identifier.citationNUKLEARMEDIZIN-NUCLEAR MEDICINE vol. 58 no. 2 p. 146en_GB
dc.identifier.issn0029-5566 (online)en_GB
dc.identifier.urihttps://www.thieme-connect.com/products/ejournals/abstract/10.1055/s-0039-1683594en_GB
dc.identifier.urihttp://publications.jrc.ec.europa.eu/repository/handle/JRC113789-
dc.description.abstractThe development of a prostate-specific membrane antigen (PSMA)-ligand for labeling with different radioisotopes of lead and the approximation of the dosimetry of a simulated Pb-212 based alpha-therapy by using its Pb-203 imaging analogue.en_GB
dc.description.sponsorshipJRC.G.I.5-Advanced Nuclear Knowledgeen_GB
dc.format.mediumOnlineen_GB
dc.languageENGen_GB
dc.publisherSCHATTAUER GMBH-VERLAG MEDIZIN NATURWISSENSCHAFTENen_GB
dc.relation.ispartofseriesJRC113789en_GB
dc.titleDevelopment and dosimetry of Pb-203 / Pb-212 labeled PSMA ligands – Bringing “the Lead” into PSMA-Targeting Alpha Therapy?en_GB
dc.typeArticles in periodicals and booksen_GB
dc.identifier.doi10.1055/s-0039-1683594 (online)en_GB
JRC Directorate:Nuclear Safety and Security

Files in This Item:
There are no files associated with this item.


Items in repository are protected by copyright, with all rights reserved, unless otherwise indicated.